 View printer-friendly version |
| << Back |
| InSite Vision to Report First Quarter 2012 Financial Results on May 1, 2012 |
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the first quarter ended March 31, 2012 on Tuesday, May 1, 2012. Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss first quarter financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions during the call following management's prepared remarks. Analysts and investors can participate in the conference call by dialing 888-680-0860 for domestic callers and 617-213-4852 for international callers using the pass code 18771192. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 21374373. The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing first quarter 2012 financial results will also be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K. About InSite Vision InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The company's product portfolio utilizes InSite Vision's proven DuraSite(R) bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite(R) (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance(R) (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision's clinical-stage ophthalmic product pipeline includes AzaSite Plus(TM) and DexaSite(TM) for the treatment of eye infections, BromSite(TM) (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit www.insitevision.com.
SOURCE: InSite Vision InSite Vision |
 |